Over the course of 2019 and 2020, with efforts continuing to date, Donovan/Green has worked to develop and launch a retention plan for a global phase 3 clinical study. The objective of the plan is to educate and motivate all participants, study subjects and study site staff alike, in order to foster the common goal of retaining subjects in this long-term outcomes trial. Our client is on the front lines of finding a treatment for a serious disease that to date has no solution other than invasive surgery. The possibilities are exciting for the team, the sites, and the study subjects. However, due to the unchartered territory and length of this trial, retention efforts are essential in order to keep all involved motivated and engaged.
The retention plan’s strategy is based in empathy and compassion. Each component of the program relies on the importance of understanding people and reinforcing the powerful effects of education and human connection on successful medical interventions.
Our plan utilizes innovative technology solutions to deliver bespoke content directly to patients — on-site via a hand-held device and at home via an online portal. Informative and motivational content of this depth and clarity is often not part of the study plan. By putting the information directly into the hands of patients, we consistently deliver materials that are approachable, understandable, and available at times when the clinicians may not be. The technology allows for easy content updating, managing permissions of global site approvals, and capturing engagement analytics to fuel future work.
The retention plan reaches more than 300 study sites in 20 countries. There are nearly 30 touchpoints of communication, several of which are translated into 16 different languages.
Donovan/Green, along with the trial sponsor, the study CRO, and other collaborators, hosted a global launch meeting to officially kick off the retention plan in December 2020. The meeting was attended by hundreds of internal and external team members from around the world. A Q&A session concluded the 70-minute webinar.
As we begin 2021, Donovan/Green is excited to continue our important work in the clinical trial space, helping to inform and inspire patients, providers, and our internal teams to move toward successful outcomes.